Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients

摘要

Even though the optimal post-remission therapy for younger acute myeloid leukemia (AML) patients has remained controversial only a few prospective trials have been comparing intensive chemotherapy to autologous (auto-) or allogeneic (allo-) bone marrow transplantation (BMT). In addition, most of these studies have been published with a relatively short follow-up. Therefore, we herein report a very long-term follow-up evaluation of AML patients previously enrolled in the pivotal EORTC/GIMEMA AML-8A trial.